Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor. This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak płuca (typ niedrobnokomórkowy)
- •Guz o wielkości co najmniej 2 cm
- •Zaplanowana operacja po chemioterapii i immunoterapii
- •Wiek powyżej 18 lat
- •Zdolność do pracy i codziennych czynności (stan ogólny 0-1)
- •Wystarczająca funkcja płuc do przeprowadzenia operacji
✗ Disqualifies
- •Stan uniemożliwiający przeprowadzenie operacji
- •Usunięty śledzion
- •Szczepienie przeciwko chorobom w ciągu 14 dni przed badaniem
- •Długotrwałe stosowanie leków hamujących układ odpornościowy
- •Zaburzenia psychiczne lub uzależnienia mogące utrudnić udział w badaniu
- •Ciąża, karmienie piersią lub planowana ciąża
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Amsterdam UMC, location VUmc
Amsterdam, Netherlands
Trial contact
Maarten Slebe, Msc.
Idris Bahce, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.